In a recent case series, Kruzer et al.[49] characterized ANA+ SSc patients lacking SSc-specific ACA, ATA, and ARA (triple negative), reporting that these individual manifested a high prevalence of anti-Ro52 antibodies, an enrichment for myositis specific antibodies, and an increased risk of ILD. This evidence concerns the gene TRIM21 and interstitial lung disease.